RESUMEN

BACKGROUND: Dual-layer stents have fallen into disrepute after several studies reported high rates of in-stent occlusions in acute stroke treatments. The CGuard stent is a new-generation hybrid dual-layer stent that has been designed to provide less thrombogenicity and to prevent peri- and postinterventional emboli. The aim of the study is to evaluate the safety and efficacy of the CGuard stent for the acute treatment of occlusion or high-grade stenosis of the extracranial internal carotid artery (ICA) in patients with acute ischemic stroke (AIS) with and without concomitant intracranial large vessel occlusion (LVO). METHODS: All patients who underwent emergent carotid artery stenting (CAS) with the CGuard stent were identified and analyzed from the stroke registries from four tertiary German stroke centers. Clinical, procedural, and imaging data were evaluated. Stent patency within 72 h, intracranial hemorrhage, and modified Rankin score (mRS) at discharge were the safety and efficacy end points. RESULTS: Overall, ninety-six patients were included (mean age 70.2 ± 11.8, 66 males (68.8%), median NIHSS score at admission 11 (7-17), IV lysis: n = 44 (45.8%)). Stent placement was successful in all patients. Eighty-three (86.4%) patients had tandem occlusions. In-stent occlusion occurred in 5 patients (5.2%) and 3 patients developed early in-stent stenosis (3.1%). Median mRS at discharge was 2 (1-4). CONCLUSION: In this multicenter study, the use of the dual-layer CGuard stent for emergent CAS, particularly in tandem occlusions, was safe and resulted in low rates of in-stent occlusions.

RESUMEN

PURPOSE: Double-layer design carotid stents have been cast in a negative light since several investigations reported high rates of in-stent occlusions, at least in the acute setting of tandem occlusions. CGuard is a new generation double-layered stent that was designed to prevent periinterventional embolic events. The aim of this study was to analyze the safety and efficacy of the CGuard in emergent CAS and for the acute treatment of tandem occlusions in comparison with the single-layer Carotid Wallstent (CWS) system. METHODS: All patients who underwent CAS with CGuard or CWS after intracranial mechanical thrombectomy (MT) between 11/2018 and 12/2022 were identified from our local thrombectomy registry. Clinical, interventional and neuroimaging data were analyzed. Patency of the stent was assessed within 72 h. Intracranial hemorrhage and modified Rankin score (mRS) at discharge were the main endpoints. RESULTS: In total, 86 stent procedures in 86 patients were included (CWS: 44, CGuard: 42). CGuard had a lower, but not statistically significant rate (p = 0.431) of in-stent occlusions (n = 2, 4.8%) when compared to the CWS (n = 4, 9.1%). Significant in-stent stenosis was found in one case in each group. There was no statistically significant difference in functional outcome at discharge between the two groups with a median mRS for CGuard of 2 (IQR:1-5) vs. CWS 3 (IQR:2-4). CONCLUSION: In our series, the rate of in-stent occlusions after emergent CAS was lower with the dual-layer CGuard when compared to the monolayer CWS. Further data are needed to evaluate the potential benefit of the design in more detail.

Asunto(s)

Estenosis Carotídea , Stents , Humanos , Masculino , Femenino , Estenosis Carotídea/diagnóstico por imagen , Estenosis Carotídea/cirugía , Anciano , Estudios Retrospectivos , Diseño de Prótesis , Trombectomía/métodos , Persona de Mediana Edad , Anciano de 80 o más Años

RESUMEN

BACKGROUND: Drug-eluting devices improved outcomes of endovascular therapy (EVT) for femoropopliteal lesions, but mainly for de novo lesions. Endovascular therapy for in-stent restenosis/occlusion (ISR/O) is challenging, and large trials and long-term data are not well reported. MATERIALS AND METHODS: This study is a physician initiated, multicenter, and retrospective design. From 7 Japanese institutes, 3635 femoropopliteal cases were enrolled in the study. Among these, 346 cases of first ISR/O were studied. We defined drug-coated-balloon, drug-eluting stent, and covered stent as New devices. Balloon angioplasty and bare nitinol stent were included in the control group. RESULTS: The propensity score matching extracted 112 pairs. At 12 months, the primary patency rate was 80.3% in the new device group and 52.7% in the control group, and there was a significant intergroup difference (P = .004). However, at 36 months, the rate was 43.3% vs 39.2%, with no significant difference (P = .090). No baseline characteristics had any significant interaction effect (all P > .05). CONCLUSIONS: The New devices were more effective than the control group for ISR/O at 1 year, but caught up at 3 years.

Asunto(s)

Angioplastia de Balón , Materiales Biocompatibles Revestidos , Stents Liberadores de Fármacos , Arteria Femoral , Enfermedad Arterial Periférica , Arteria Poplítea , Diseño de Prótesis , Recurrencia , Stents , Grado de Desobstrucción Vascular , Humanos , Arteria Femoral/fisiopatología , Arteria Femoral/diagnóstico por imagen , Arteria Poplítea/fisiopatología , Arteria Poplítea/diagnóstico por imagen , Enfermedad Arterial Periférica/terapia , Enfermedad Arterial Periférica/fisiopatología , Enfermedad Arterial Periférica/diagnóstico por imagen , Masculino , Estudios Retrospectivos , Femenino , Anciano , Factores de Tiempo , Resultado del Tratamiento , Angioplastia de Balón/instrumentación , Angioplastia de Balón/efectos adversos , Japón , Factores de Riesgo , Persona de Mediana Edad , Anciano de 80 o más Años , Aleaciones , Dispositivos de Acceso Vascular , Constricción Patológica , Estudios de Seguimiento

RESUMEN

CLINICAL IMPACT: Based on our study, no antithrombotic therapy is significantly associated with bridging stent occlusion, and no evidence of the superiority of other antithrombotic therapy exists. Nevertehless, due to the low number of bridging stent occlusions, this study can neither support nor reject the PRINCE2SS recommendations. Further studies with larger cohorts are needed to determine clear guideliness of the best antithrombotic treatment regimen after complex enfovascular aortic repair.

RESUMEN

PURPOSE: To report the performance of surgical treatment (ST), hybrid treatment (HT), and endovascular treatment (ET) for patients with acute limb ischemia (ALI). METHODS: This is a retrospective, comparative study of all consecutive patients with ALI treated in 2 tertiary centers between April 2010 and April 2020. Amputation and/or death (amputation-free survival; AFS) was the primary composite endpoint. Mortality, major amputation, and reintervention during follow-up were additionally analyzed. Proportional hazards modeling was used to identify confounders, results are presented as hazard ratio (HR) and 95% confidence intervals (CIs). RESULTS: In total, 395 patients (mean age=71.1±13.6 years; 51.1% female) were treated during the study period. Surgical treatment was preferred in 150 patients (38%), while 98 were treated by HT (24.8%) and 147 by ET (37.2%). Rutherford class IIa was the most common clinical presentation in the ET group (50.3%), whereas Rutherford IIb was most common in the ST (54%) and HT (48%) groups (p<0.001). Significantly, more patients presented with a de novo lesion in the ST and HT groups (79.3% and 64.3%, respectively) compared with ET (53.7%; p<0.001). Median follow-up was 20 months (range=0-111 months). In the multivariate analysis, ET showed significantly better AFS during follow-up compared with ST (HR=1.89, 95% CI=1.2-2.9, p<0.001) and HT (HR=1.73, 95% CI=1.1-3.1, p<0.001). Mortality during follow-up was also significantly lower after ET compared with ST (HR=2.21, 95% CI=1.31-3.74, p=0.003) and HT (HR=2.04, 95% CI=1.17-3.56, p=0.012). Endovascular treatment was associated with lower amputation rate compared with ST (HR=2.27, 95% CI=1.19-4.35, p=0.013) but was comparable with HT (HR=2.00, 95% CI=0.98-4.06, p=0.055). Reintervention rates did not differ significantly between the groups (ET vs ST: HR=1.52, 95% CI=0.99-2.31, p=0.053; ET vs HT: HR=1.3, 95% CI=0.81-2.07, p=0.27). CONCLUSION: Endovascular treatment for ALI was associated with improved AFS and comparable reintervention rates compared with open surgical and hybrid therapy. CLINICAL IMPACT: Treatment of acute lower limb ischemia remains a challenge for clinicians with high morbidity and mortality rates. Endovascular revascularization is considered first line treatment for many and hybrid treatments are becoming more common, however data is limited to either old trials, small series or with short follow-up. We present herein our 10-year experience with all available devices and techniques for open surgical, endovascular and hybrid acute limb ischemia treatments and compare their outcomes.

RESUMEN

BACKGROUND: In-stent thrombotic occlusion is a serious ischemic complication that can also result in ischemia in the distal perfusion territory and the territory of side branches for the artery in which the flow diverter (FD) stent is deployed. OBSERVATIONS: A 49-year-old female with a large paraclinoid internal carotid artery (ICA) aneurysm was treated with an FD involving the orifice of the anterior cerebral artery (ACA). The antiplatelet dose was reduced because of an increased clopidogrel response postintervention. The patient developed aphasia 2 months later. Emergency magnetic resonance imaging and digital subtraction angiography of the brain indicated FD stent occlusion and a small infarct in the distal vascular territory of the ipsilateral ICA, but the anterior choroidal artery (AChoA) territory was preserved by collateral flow. Emergency superficial temporal artery to middle cerebral artery anastomosis was performed, and she was discharged without neurological deficit 2 weeks after the second operation. LESSONS: In-stent occlusion after FD deployment involving the orifice of the ACA can cause severe cerebral ischemia that requires an adequate antiplatelet effect and careful follow-up. The AChoA territory can be preserved by collateral blood flow even in cases of in-stent occlusion.

RESUMEN

Background: Currently, it is unknown whether iodine-125 (125I) stent implantation has the same therapeutic effect on patients with malignant biliary obstruction (MBO) caused by different cancers. This meta-analysis aimed to investigate whether 125I implantation in patients with MBO is superior to biliary stent placement in efficacy and safety, and to further explore the difference in efficacy and safety of seed implantation in different patients through subgroup analysis. Methods: A systematic search of the PubMed, Wiley Online Library, Cochrane library, Google Scholar, the Web of Science, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang databases was conducted to screen all relevant studies up to October 30, 2022. Articles were not subjected to language or geographical limitations, but were required to meet the inclusion and exclusion criteria for this study. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of articles. The primary endpoint was survival, which was defined as the interval between initial treatment and death or the end of study. Meta analysis was performed using Stata/SE15.0. Results: A total of 12 eligible studies were enrolled including 679 patients. All the included studies were single-center studies carried out in China. The results showed that the death risk and stent occlusion risk in the 125I group was 0.441 times [95% confidence interval (CI): 0.315 to 0.619, P<0.001; I2=0%, fixed, IV] and 0.534 times (95% CI: 0.433 to 0.658, P=0.003; I2=45.4%, fixed, IV) lower than the control group, respectively. There was no significant statistical difference in the risk of complications between the 2 groups [risk ratio (RR) =1.024, 95% CI: 0.963 to 1.090, P=0.450; PQ=0.640; I2=0%]. The reduction level of total bilirubin [TBIL; weighted mean differences (WMDs) =-14.969, 95% CI: -28.670 to -1.267, P=0.032; PQ=0.409, I2=2.1%) and aspartate transaminase (AST; WMD =-14.653, 95% CI: -23.246 to -6.060, P=0.001; PQ=0.900, I2=0%) in the 125I group was higher than that in the control group 1 week after surgery. The efficacy and safety of 125I for MBO patients were found to be independent of the type of tumor causing MBO (P for meta regression >0.05). Conclusions: For patients with MBO caused by hilar tumor or other tumors, 125I seed implantation can reduce the death risk and stent occlusion risk, prolong the time of survival and stent patency, and does not increase the complication risk. Due to the limitations of the study population, these findings should be further validated in other populations and regions.

RESUMEN

PURPOSE: The study aimed to evaluate the efficacy of heparin packing after antegrade ureteral stent placement in the renal pelvis to protect against early dysfunction. METHOD: From December 2019 to September 2021, 44 double J (DJ) stent placements were performed with heparin packing (heparin packing group). Between February 2008 and March 2014, 250 DJ stent placements without heparin packing were performed (control group). One-week patency and 3-month patency of the two groups were compared. The patency of the DJ stent according to the blood retention grade in the urinary system was also compared by subgroup analysis. RESULT: The 1-week patency rate in the heparin packing group was significantly higher compared to the control group (88.6% and 65.2%, respectively, p = 0.002). There was no significant difference in the 3-month patency rate between the two groups (72.7% and 60.9%, respectively; p = 0.187). In the subgroup analysis, among the patients with high blood retention grades, the 1-week patency rates of the heparin packing group were significantly higher than that of the control group (100% and 60.9%, respectively; p < 0.001). CONCLUSION: Heparin packing through the catheter after DJ stent installation aids in DJ stent patency.

Asunto(s)

Uréter , Obstrucción Ureteral , Neoplasias de la Vejiga Urinaria , Humanos , Obstrucción Ureteral/cirugía , Heparina , Uréter/cirugía , Pelvis Renal , Stents , Estudios Retrospectivos

Asunto(s)

Hipersensibilidad , Síndrome de Kounis , Humanos , Vanadio , Hipersensibilidad/diagnóstico , Pruebas del Parche

RESUMEN

OBJECTIVE: The goal of endovenous stenting is to relieve venous obstruction and reduce peripheral venous hypertension by using large caliber venous stents in the presence of adequate venous inflow and outflow for the stented conduit. The aim of this report is to describe the technical reasons and outcomes for reinterventions in a subset of patients who had a history of iliac vein stenting and were now referred to us at a specialty venous clinic for further care. METHODS: From January 2016 to December 2021, records of all patients who were referred to us with a history of iliac vein stenting performed at an outside facility and who had a reoperation performed at our center were retrospectively analyzed. RESULTS: A total of 149 limbs underwent a deep venous reintervention after a failure of a trial of conservative therapy. The mean age of the sample was 57 ± 16 years. The ratio of non-thrombotic iliac vein lesions to post-thrombotic lesions was 1:2.5. The majority of the patients (84%) were CEAP class C4 or higher. The most common reason for reintervention was stent occlusion (74%), followed by iatrogenic stenosis (53%) and in-stent restenosis/shelving (38%). There was a trend for improvement in all clinical parameters (venous clinical severity score, visual analog scale for pain, and edema grade) after the reintervention. Poor inflow was present in 70% of limbs with stent occlusion. The median diameters of stented common femoral vein, external iliac vein, and common iliac vein prior to reintervention were 12, 12, and 13 mm, respectively. The median diameters of stented common femoral vein, external iliac vein, and common iliac vein after reintervention were 14, 15, and 16 mm, respectively. Eighty-eight percent of limbs required at least one further reintervention after initial reoperation. CONCLUSIONS: Venous reoperations are generally infrequent and required in a small number of patients. Poor inflow appeared to be a common cause of stent occlusion. Iatrogenic stenosis is another common reason for venous reoperation and is difficult to fully rectify through current endovascular techniques and tools. Use of intravascular ultrasound planimetry routinely in every deep venous intervention and thorough knowledge of the principles of venous stenting outlined in this report may help forestall the need for reoperative deep venous surgery in some cases.

Asunto(s)

Vena Ilíaca , Stents , Humanos , Adulto , Persona de Mediana Edad , Anciano , Constricción Patológica , Estudios Retrospectivos , Resultado del Tratamiento , Enfermedad Iatrogénica

RESUMEN

The authors report a case in which an acute thrombosis of a pre-existing arterial stent occurs in a patient's lower extremity during a lumbar spinal fusion surgery. The event was detected by acute changes in somatosensory evoked potentials (SSEPs) which were being monitored during the procedure. The neurophysiology technologist reported a 10 % increased latency and 50 % loss of amplitude in the left posterior tibial nerve recordings. While still in the operating room, further investigation, including doppler and arteriogram, demonstrated a complete occlusion of one of the two contiguous stents within the superficial femoral artery (SFA). A vascular surgeon was then able to emergently perform trans-arterial thrombectomy and restore flow through the extremity while still in the operating room. The observed events demonstrate the ability of SSEP monitoring to potentially detect arterial occlusion early, allowing for a rapid diagnosis and expedient treatment, in this case immediate, thus avoiding significant limb threatening morbidity.

Asunto(s)

Arteriopatías Oclusivas , Monitoreo Intraoperatorio , Humanos , Monitoreo Intraoperatorio/métodos , Potenciales Evocados Somatosensoriales/fisiología , Extremidad Inferior , Arteriopatías Oclusivas/diagnóstico , Arteriopatías Oclusivas/cirugía , Stents , Potenciales Evocados Motores/fisiología

RESUMEN

BACKGROUND: Management of extracranial internal carotid artery steno-occlusive lesion during endovascular therapy remains debated. Stent occlusion within 24 hours of endovascular therapy is a frequent event after acute carotid artery stenting, and we currently lack large population results. We investigated the incidence, predictors, and clinical impact of stent occlusion after acute carotid artery stenting in current clinical practice. METHODS: Patients treated by endovascular therapy with acute carotid artery stenting between 2015 and 2019 in 5 large-volume endovascular-capable centers were retrospectively analyzed. Patients were separated in 2 groups according to the stent patency at 24 hours after carotid artery stenting. We compared baseline characteristics, treatment modalities, and clinical outcome depending on 24-hour stent patency. Primary end point was favorable outcome, defined as a modified Rankin Scale score 0-2 at 3 months. RESULTS: A stent occlusion was observed in 47/225 patients (20.9%). Patients with stent patency had a lower baseline National Institutes of Health Stroke Scale (median [interquartile range]: 13 [7-17] versus 18 [12-21]) and had more often stroke of atherothrombotic origin (77.0% versus 53.2%). A higher stent patency rate was found for patients treated with P2Y12 antagonists at the acute phase (odds ratio [OR]' 2.95 [95% CI' 1.10-7.91]; P=0.026) and treated with angioplasty (OR' 2.42 [95% CI' 1.24-4.67]; P=0.008). A better intracranial angiographic reperfusion was observed in patients with 24-hour stent patency compared with patients without stent patency (OR' 8.38 [95% CI' 3.07-22.78]; P<0.001). Patients with a stent patency at 24 hours had a higher chance of favorable outcome (OR' 3.29 [95% CI, 1.66-6.52]; P<0.001) and a lower risk of death (OR' 0.32 [95% CI, 0.13-0.76]; P=0.009). CONCLUSIONS: One out of 5 patients treated with carotid artery stenting during endovascular therapy presented a stent occlusion within 24 hours. This event was associated with worse functional outcome. Stroke etiology, P2Y12 antagonist administration, quality of intracranial reperfusion, and angioplasty were associated with 24-hour stent patency.

Asunto(s)

Estenosis Carotídea , Procedimientos Endovasculares , Accidente Cerebrovascular , Humanos , Estenosis Carotídea/diagnóstico por imagen , Estenosis Carotídea/cirugía , Estudios Retrospectivos , Stents/efectos adversos , Procedimientos Endovasculares/métodos , Resultado del Tratamiento , Trombectomía/métodos , Arterias Carótidas , Accidente Cerebrovascular/diagnóstico por imagen , Accidente Cerebrovascular/cirugía , Accidente Cerebrovascular/etiología

Asunto(s)

Humanos , Masculino , Persona de Mediana Edad , Hipersensibilidad/diagnóstico , Hipersensibilidad/etiología , Metales/efectos adversos , Stents/efectos adversos , Vanadio/efectos adversos , Síndrome de Kounis/cirugía

RESUMEN

Background: This study aimed to identify the risk factors for stent occlusion in patients with iliofemoral deep vein thrombosis (DVT) secondary to May-Thurner syndrome (MTS) who underwent catheter-directed thrombolysis (CDT) and iliac vein stenting. Methods: A retrospective analysis was performed on 44 patients who underwent CDT and iliac vein stenting for MTS with iliofemoral DVT between October 2001 and March 2018. MTS was diagnosed based on extrinsic compression of the left common iliac vein (CIV) by the overlying right common iliac artery (CIA) on computed tomography (CT). Clinical records of the study population were reviewed to collect baseline data, procedural characteristics, and outcomes. Final venograms showing diffuse and irregular wall thickening in the iliofemoral vein were considered to indicate a chronic post-thrombotic lesion. The stent position was categorized as follows: confluence coverage without touching the contralateral inferior vena cava (IVC) wall, IVC extension contacting the contralateral IVC wall, or distal to the iliocaval junction. Stent patency was assessed using duplex ultrasonography. Risk factors for stent occlusion were assessed using univariate and multivariate Cox proportional hazard models. Results: The median duplex ultrasound follow-up period was 25 months (range, 1-196 months). The overall cumulative patency rate at 12 months was 70.0%. In the univariate Cox regression, factors significantly associated with stent occlusion included symptom duration >2 weeks before CDT, partial thrombolysis (50-99% of thrombus removal), chronic post-thrombotic lesions, and stent position. Multivariate Cox regression showed that chronic post-thrombotic lesions [hazard ratio (HR) =7.15; 95% confidence interval (CI): 1.32-38.81; P=0.023] and a stent distal to the iliocaval junction (HR =5.59; 95% CI: 1.46-21.38; P=0.012) were significantly associated with stent occlusion. Conclusions: Chronic post-thrombotic lesion and a stent distal to the iliocaval junction were important risk factors for stent occlusion in patients who underwent CDT and iliac vein stenting.

RESUMEN

Introduction: The introduction of a carotid stent involves the use of effective antiplatelet therapy to maintain stent patency. We present a case report of combined acute revascularization in a patient with occlusion in recently introduced stents of both carotid arteries. Methods: The patient (male, 73 years) was admitted for stroke recurrence upon discontinuation of antiplatelet therapy. According to the CTA, the closure of implanted stents of both carotid arteries was confirmed. Intravenous thrombolysis and mechanical thrombectomy were performed with complete recanalization of the left carotid stent. At 3 days apart, clinical deterioration was found with progressive stent restenosis. Percutaneous transluminal stent angioplasty, mechanical embolectomy and prolonged low-dose intravenous thrombolysis have been used repeatedly. Results: With the impossibility of maintaining the patency of carotid stents even on the maximum drug therapy and despite endovascular procedures, bilateral neurosurgical revascularization of the middle cerebral arteries using ECIC bypasses was successfully performed. Prolonged low-dose intravenous thrombolysis (20 mg recombinant plasminogen aktivator (rTPA)/10 h) has proven to be an acute bridging therapy until surgery. Conclusion: Early occlusion of the carotid stent is a significant complication of endovascular treatment of stenotic arteries. ECIC bypass revascularization of the middle cerebral artery can be a highly effective therapeutic procedure.

RESUMEN

Background The objective of the GNOCCI (Glasgow Natural History Study of Covered Stent Coronary Interventions) Study was to report the incidence and outcomes of coronary artery perforations over an 18-year period at a single, high-volume percutaneous coronary intervention center. We considered both the temporal trends and long-term outcomes of covered stent deployment. Methods and Results We evaluated procedural and long-term clinical outcomes following coronary perforation in a cohort of 43,343 consecutive percutaneous coronary intervention procedures. Procedural major adverse cardiac events were defined as a composite of death, myocardial infarction, stroke, target vessel revascularization, or cardiac surgery within 24 hours. A total of 161 (0.37%) procedures were complicated by coronary perforation of which 57 (35%) were Ellis grade III. Incidence increased with time over the study period (r=0.73; P<0.001). Perforation severity was linearly associated with procedural mortality (median 2.9-year follow-up): Ellis I (0%), Ellis II (1.7%), Ellis III/IIIB (21%), P<0.001. Procedural major adverse cardiac events occurred in 47% of patients with Ellis III/IIIB versus 13.5% of those with Ellis I/II perforations (odds ratio, 5.8; 95% CI, 2.7-12.5; P<0.001). Covered stents were associated with an increased risk of stent thrombosis at 2.9-year follow-up (Academic Research Consortium definite or probable; 9.1% versus 0.9%; risk ratio, 10.5; 95% CI, 1.1-97; P=0.04). Conclusions The incidence of coronary perforation increased between 2001 and 2019. Severe perforation was associated with higher procedural major adverse cardiac events and was an independent predictor of long-term mortality. Although covered stents are a potentially lifesaving treatment, the generation of devices used during the study period was limited by their efficacy and high risk of stent thrombosis. Registration Information Clinicaltrials.gov. Identifier: NCT03862352.

Asunto(s)

Enfermedad de la Arteria Coronaria , Lesiones Cardíacas , Intervención Coronaria Percutánea , Trombosis , Lesiones del Sistema Vascular , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/cirugía , Humanos , Diseño de Prótesis , Factores de Riesgo , Stents/efectos adversos , Trombosis/etiología , Resultado del Tratamiento , Lesiones del Sistema Vascular/etiología

RESUMEN

Occlusion is a challenging complication of endovenous stenting. The treatment of chronic iliofemoral stent occlusion involves wire recanalization followed by balloon angioplasty. However, this approach will not always be successful. To treat such cases, we have successfully used a laser recanalization technique in 34 limbs (31 patients). This technique involved the use of a laser to first create a channel through the chronically occluded stent, followed by balloon angioplasty to improve the caliber of this recanalized tract. The mean age of the patients was 52 ± 13.6 years (range, 24-73 years). No adverse events related to the use of the laser occurred. Following laser recanalization, the venous clinical severity score had improved from 8.2 ± 4 to 5.1 ± 3.3 (P < .0001). The visual analog scale score for pain had improved from 7.8 ± 2.5 to 4.9 ± 3 (P = .0009). The grade of swelling had improved from 2.7 ± 1.3 to 1.6 ± 1.4 (P = .0001). At 12 months after intervention, the primary stent patency was 60% (standard error of the mean, 9.3%), and the secondary stent patency was 80%. Excimer laser recanalization of chronically occluded venous stents appears to be a rarely required but useful modality with reasonable clinical outcomes. Further reinterventions might be required to maintain long-term stent patency.

Asunto(s)

Sistema Biliar , Litotricia , Coagulación con Plasma de Argón , Humanos , Stents

RESUMEN

BACKGROUND: The purpose of this study was to assess the feasibility and outcomes of recanalization and subsequent HeRO graft outflow component insertion across stent interstices in patients with an otherwise abandoned upper extremity. METHODS: Over a 10-year period, 15 patients underwent central venous recanalization by interventional radiology across the interstices of one or more occluded stents for the purpose of subsequent HeRO graft creation. A tunneled central venous catheter was left across the stent and occlusions with tip in right atrium. On a later date, the catheter was used for rapid guidewire access for HeRO graft implantation in the OR by vascular surgery. Procedural and clinical outcomes were determined by retrospective review. Primary and secondary HeRO graft patency rates were estimated with the Kaplan-Meier technique. RESULTS: The technical success rates of recanalization across stent interstices was 100% (15/15). Between one and four overlapping stent walls were traversed. The technical success of the patients who underwent attempted HeRO graft implantation with outflow component traversing across stent interstices was 91% (11/12). No major complications were encountered with either recanalization or HeRO graft implantation. The primary and secondary HeRO patency rates at 12 months were 64% and 80%, respectively. CONCLUSION: HeRO graft insertion across stent interstices is feasible and can provide effective permanent AV access; thus, the presence of stents across the subclavian and brachiocephalic veins should not be considered a contraindication.

Asunto(s)

Oclusión Coronaria , Intervención Coronaria Percutánea , Oclusión Coronaria/diagnóstico por imagen , Oclusión Coronaria/cirugía , Humanos , Intervención Coronaria Percutánea/efectos adversos , Stents , Resultado del Tratamiento